# Fludeoxyglucose F 18 in Detecting Lymph Node Metastasis in Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed by Surgery

> **NCT00732563** · NA · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 100 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** chemotherapy
- **PROCEDURE:** lymphadenectomy
- **PROCEDURE:** neoadjuvant therapy
- **PROCEDURE:** quality-of-life assessment
- **PROCEDURE:** therapeutic conventional surgery
- **PROCEDURE:** thoracic surgical procedure
- **RADIATION:** fludeoxyglucose F 18
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00732563
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07-16
- **Primary completion:** 2012-06-29
- **Final completion:** 2017-07-26
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2017-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00732563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00732563, "Fludeoxyglucose F 18 in Detecting Lymph Node Metastasis in Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed by Surgery". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00732563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*